What Is CBG?
Cannabigerol (CBG) is a non-intoxicating cannabinoid often referred to as the "mother cannabinoid" because cannabigerolic acid (CBGA) is the biosynthetic precursor from which CBD, THC, and CBC are derived. As the cannabis plant matures, enzymes convert CBGA into other cannabinoids, leaving only small amounts of CBG in the final plant — making CBG-rich extracts more difficult and costly to produce.
CBG's Receptor Pharmacology
Unlike CBD, which has low affinity for cannabinoid receptors, CBG interacts directly with both CB1 and CB2 receptors as a partial agonist. This dual-receptor activity gives CBG a distinct pharmacological profile:
- CB1 receptor partial agonism — may support focus, mood, and neurological function
- CB2 receptor activity — associated with immune modulation and anti-inflammatory signaling
- Alpha-2 adrenoceptor interaction — linked to potential blood pressure and stress regulation
- 5-HT1A serotonin receptor antagonism — may influence mood and anxiety pathways differently than CBD
Anti-Inflammatory Research
A 2013 study published in Biochemical Pharmacology by Borrelli et al. investigated CBG in a murine model of inflammatory bowel disease. The researchers found that CBG reduced nitric oxide production, decreased reactive oxygen species formation, and reduced inflammatory markers in colon tissue. The authors concluded that CBG "deserves consideration for clinical experimentation in IBD."
A 2021 study in Cannabis and Cannabinoid Research surveyed CBG users and found respondents reported using CBG primarily for anxiety, depression, chronic pain, and insomnia — with a majority reporting CBG to be "more effective" than conventional medications for these conditions.
Neuroprotective Potential
A 2015 study by Valdeolivas et al. published in Neurotherapeutics examined CBG in a mouse model of Huntington's disease. The researchers found that CBG acted as a neuroprotectant, improving motor deficits and preserving striatal neurons. The authors described CBG as "an extremely active neuroprotective agent."
Antibacterial Properties
A 2020 study published in ACS Infectious Diseases by Farha et al. identified CBG as a potent antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA). CBG disrupted the bacterial membrane and demonstrated efficacy in a mouse skin infection model.
cbdDR's CBG Formulation
Our 800mg CBG-Rich Tincture delivers 650mg CBG as the primary active cannabinoid per 30ml bottle, supported by 50mg each of CBD, CBC, and CBN. Zero THC, MCT oil carrier, independently tested every batch. Results published in our Batch Database. Learn more about CBG's science and mechanisms or explore our full anti-inflammatory collection.
Note: cbdDR does not make disease treatment or prevention claims. The research cited above is preclinical or observational. Consult a qualified healthcare provider for medical advice.
References
- Borrelli F, et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316. PMID: 23415610
- Valdeolivas S, et al. (2015). Neuroprotective properties of cannabigerol in Huntington's disease. Neurotherapeutics, 12(1), 185–199. PMID: 25252936
- Farha MA, et al. (2020). Uncovering the Hidden Antibiotic Potential of Cannabis. ACS Infectious Diseases, 6(3), 338–346. PMID: 31971016
- Russo EB, et al. (2021). Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations. Cannabis and Cannabinoid Research, 6(1), 43–51. PMID: 33614949